Ani Pharmaceuticals (ANIP) EBIT (2016 - 2025)
Historic EBIT for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $36.2 million.
- Ani Pharmaceuticals' EBIT rose 27661.68% to $36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.9 million, marking a year-over-year increase of 51557.15%. This contributed to the annual value of $584000.0 for FY2024, which is 9875.67% down from last year.
- Per Ani Pharmaceuticals' latest filing, its EBIT stood at $36.2 million for Q3 2025, which was up 27661.68% from $13.9 million recorded in Q2 2025.
- Over the past 5 years, Ani Pharmaceuticals' EBIT peaked at $36.2 million during Q3 2025, and registered a low of -$23.7 million during Q4 2021.
- Over the past 5 years, Ani Pharmaceuticals' median EBIT value was $3.0 million (recorded in 2021), while the average stood at $2.6 million.
- Its EBIT has fluctuated over the past 5 years, first crashed by 726706.95% in 2021, then surged by 45931.93% in 2023.
- Over the past 5 years, Ani Pharmaceuticals' EBIT (Quarter) stood at -$23.7 million in 2021, then surged by 107.67% to $1.8 million in 2022, then surged by 269.56% to $6.7 million in 2023, then tumbled by 165.09% to -$4.4 million in 2024, then surged by 927.78% to $36.2 million in 2025.
- Its EBIT stands at $36.2 million for Q3 2025, versus $13.9 million for Q2 2025 and $26.2 million for Q1 2025.